HC Wainwright Has Negative Estimate for TYRA FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 earnings forecast for Tyra Biosciences to a loss of $2.64 per share from a projected loss of $2.60, while maintaining a Buy rating and $27 price target.
• Tyra reported a quarterly loss of $0.74 per share, missing the consensus estimate of a $0.67 loss; shares were reported down 5.8% and opened at $19.76.
• Analyst sentiment remains broadly positive: MarketBeat lists a Moderate Buy consensus rating and an average price target of $47.40, though ratings range from Strong Buy to Sell.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - HC Wainwright decreased their FY2026 earnings estimates for shares of Tyra Biosciences in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.64) per share for the year, down from their prior estimate of ($2.60). HC Wainwright currently has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.44) EPS.

TYRA has been the topic of a number of other reports. Wedbush raised their price target on Tyra Biosciences from $53.00 to $57.00 and gave the company an "outperform" rating in a research note on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Jefferies Financial Group reaffirmed a "buy" rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, William Blair raised Tyra Biosciences to a "strong-buy" rating in a research report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $47.40.

Tyra Biosciences Trading Down 5.8%

Shares of TYRA stock opened at $19.76 on Friday. The firm has a fifty day moving average price of $21.85 and a 200 day moving average price of $29.44. Tyra Biosciences has a 12 month low of $14.67 and a 12 month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07).

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC raised its stake in Tyra Biosciences by 843.4% during the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company's stock worth $27,000 after acquiring an additional 1,088 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Tyra Biosciences by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company's stock valued at $239,000 after acquiring an additional 1,424 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Tyra Biosciences by 10.7% in the first quarter. Public Employees Retirement System of Ohio now owns 20,522 shares of the company's stock valued at $786,000 after acquiring an additional 1,980 shares in the last quarter. State of Wyoming acquired a new position in Tyra Biosciences in the second quarter valued at $76,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Tyra Biosciences in the third quarter valued at $67,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company's pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.